ADPT - Adaptive Biotechnologies Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.19
+0.39 (+1.46%)
At close: 4:00PM EST

27.19 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close26.80
Open26.56
Bid27.17 x 800
Ask27.19 x 900
Day's Range26.56 - 27.69
52 Week Range24.05 - 55.12
Volume1,473,424
Avg. Volume750,153
Market Cap3.381B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.51
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.75
  • Benzinga

    The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 21) Abbott Laboratories (NYSE: ABT ) Apellis Pharmaceuticals ...

  • GlobeNewswire

    Adaptive Announces Proposed Public Offering of Common Stock

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders. In addition, certain selling shareholders expect to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock in the offering. Adaptive will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling shareholders.

  • GlobeNewswire

    Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today preliminary unaudited revenue for the full year 2019. “We are pleased with our strong performance in the fourth quarter, as we continued accelerating our efforts to scale our business to aggressively pursue the large pipeline opportunity in front of us,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies.

  • GlobeNewswire

    Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global diagnostic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax in the registrational Phase III CRISTALLO (CO41685) study for the treatment of newly diagnosed people with chronic lymphocytic leukemia (CLL) plus additional future venetoclax studies in CLL. Adaptive and Genentech will partner to incorporate the clonoSEQ Assay to measure MRD status as a primary endpoint in this registrational study.

  • GlobeNewswire

    Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its MolDX program, has expanded coverage of the clonoSEQ Assay to include monitoring minimal residual disease (MRD) in Medicare patients with chronic lymphocytic leukemia (CLL). This adds to existing Medicare coverage in B-cell acute lymphoblastic leukemia (ALL) and multiple myeloma, which was established in January 2019.

  • GlobeNewswire

    Adaptive Biotechnologies to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (ADPT), today announced the company will be participating in the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

  • Top Ranked Momentum Stocks to Buy for December 30th
    Zacks

    Top Ranked Momentum Stocks to Buy for December 30th

    Top Ranked Momentum Stocks to Buy for December 30th

  • Tech will drive change in health care throughout next decade
    American City Business Journals

    Tech will drive change in health care throughout next decade

    Partnerships between tech companies and those in health care and biotech will change how Americans use health care in the 2020s, experts predict.

  • Is Adaptive Biotechnologies Corporation (ADPT) A Good Stock To Buy?
    Insider Monkey

    Is Adaptive Biotechnologies Corporation (ADPT) A Good Stock To Buy?

    The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]

  • Chad Robins led Adaptive Biotechnologies through a huge 2019
    American City Business Journals

    Chad Robins led Adaptive Biotechnologies through a huge 2019

    Chad Robins, CEO and president of Adaptive Biotechnologies, led the Seattle company through one of the largest biotech IPOs of the year. Its mission is to map the human immune system to identify and treat diseases. “We went public because we had a tremendous business opportunity to execute on our vision of the immune medicine platform,” Robins said.

  • Adaptive Biotechnologies Shares March Higher, Can It Continue?
    Zacks

    Adaptive Biotechnologies Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor Adaptive Biotechnologies.

  • Fiverr Languishes Below IPO Price as First Chance to Sell Nears
    Bloomberg

    Fiverr Languishes Below IPO Price as First Chance to Sell Nears

    (Bloomberg) -- Fiverr International Ltd.’s initial zing has almost entirely faded since its June IPO, with the stock falling for six straight days to below its IPO price as insiders’ and early investors’ first chance to sell looms on Tuesday.The biggest stakeholders include Viola Private Equity’s Jonathan Kolber, Deer VII & Co., Accel London III Associates, Square Peg Group, and co-founder and chief executive officer Micha Kaufman, according to data compiled by Bloomberg. But post-IPO stock weakness, with shares off the June high of $44 by more than 52%, make it less likely shareholders will walk away.Fiverr chief Kaufman was unavailable to respond to queries.The operator of an online marketplace for software services had the fourth-best debut of this year’s 239 IPOs, rising a whopping 90% from offer to its first close. That ranks just behind Beyond Meat Inc., Adaptive Biotechnologies Corp., and Cortexyme Inc., each of which has done better hanging on to initial gains. Underwriters on the Fiverr IPO were JPMorgan, Citi, BofA, UBS, Oppenheimer, Needham, and JMP Securities.Analysts appear split, with four buy, three hold and no sell ratings on the stock, according to data compiled by Bloomberg. But with price targets ranging from $22 to $34, they seem to agree that debut highs are unlikely to be seen again anytime soon. To contact the reporter on this story: Crystal Kim in New York at ckim426@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • GlobeNewswire

    Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay

    Adaptive Biotechnologies Corporation (ADPT) today announced a multi-year, global collaboration agreement with AbbVie (ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax across multiple myeloma (MM) clinical trials. “Adaptive is thrilled to partner with AbbVie to support the clinical development and potential regulatory approval of venetoclax in multiple myeloma,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. MRD is a measure of the amount of cancer in the body, specifically the very small number of cancer cells that remain during or after treatment.

  • GlobeNewswire

    Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients

    Research and real-world evidence support the use across a range of leukemias and lymphomas and demonstrate utility in multiple tissue types, including blood and bone marrow.

  • Hedge Funds Love Echostar Corporation (SATS) Way More Than These 4 Stocks
    Insider Monkey

    Hedge Funds Love Echostar Corporation (SATS) Way More Than These 4 Stocks

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • Seattle has potential as a biotech hub, but more companies must stay here and grow
    American City Business Journals

    Seattle has potential as a biotech hub, but more companies must stay here and grow

    Seattle's biotech community has a reputation for developing companies that are eventually acquired and that has restricted its growth. But a few companies are well-positioned to change that narrative.

  • Robertson's Tiger Management Buys Adobe, Facebook
    GuruFocus.com

    Robertson's Tiger Management Buys Adobe, Facebook

    Firm's largest buys of the 3rd quarter Continue reading...

  • GlobeNewswire

    Adaptive Biotechnologies Corporation Reports Third Quarter 2019 Financial Results

    SEATTLE, Nov. 12, 2019 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today reported financial results for the quarter ended September 30,.

  • 4 Biotech Stocks That Could Keep Beating Wall Street
    Zacks

    4 Biotech Stocks That Could Keep Beating Wall Street

    The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

  • GlobeNewswire

    Adaptive Biotechnologies to Report Third Quarter Financial Results on November 12, 2019

    Adaptive Biotechnologies (ADPT) today announced that it will report financial results for the third quarter of 2019 after market close on Tuesday, November 12, 2019. Investors interested in listening to the conference call may do so by dialing (800) 361-2311 for U.S. callers or (409) 937-8761 for international callers (Conference ID: 3698520). Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

  • Hedge Funds Have Never Been This Bullish On Adaptive Biotechnologies Corporation (ADPT)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Adaptive Biotechnologies Corporation (ADPT)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits
    Zacks

    Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits

    Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.

  • Do Insiders Own Shares In Adaptive Biotechnologies Corporation (NASDAQ:ADPT)?
    Simply Wall St.

    Do Insiders Own Shares In Adaptive Biotechnologies Corporation (NASDAQ:ADPT)?

    If you want to know who really controls Adaptive Biotechnologies Corporation (NASDAQ:ADPT), then you'll have to look...

  • Illumina (ILMN) Inks Deal to Develop Distributable Test Kits
    Zacks

    Illumina (ILMN) Inks Deal to Develop Distributable Test Kits

    Illumina (ILMN) aims to expand access to genomic-based testing and improve patient outcome through the new partnership deal.

  • GlobeNewswire

    Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partnership with Illumina, Inc. (ILMN) to develop in-vitro diagnostic (IVD) test kits for Adaptive’s current and future portfolio of next-generation sequencing (NGS)-based immunodiagnostics. The test kits under development would expand the availability of Adaptive’s clonoSEQ® Assay for assessing and monitoring minimal residual disease (MRD) for the management of patients with certain blood cancers and immunoSEQ Dx™ Assay for pipeline applications.